A Randomized Pilot Study Evaluating Combination Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Plus Metformin Compared to Metformin Monotherapy and Placebo on Metabolic Abnormalities in Women With a Recent History of GDM

Trial Profile

A Randomized Pilot Study Evaluating Combination Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Plus Metformin Compared to Metformin Monotherapy and Placebo on Metabolic Abnormalities in Women With a Recent History of GDM

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Metformin/sitagliptin (Primary) ; Metformin
  • Indications Gestational diabetes
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 29 Aug 2017 Planned End Date changed from 1 Feb 2018 to 1 Oct 2017.
    • 29 Aug 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Sep 2017.
    • 13 Jun 2017 Primary endpoint has been met. (Surrogate measures of insulin sensitivity and secretion), according to results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top